Day One

• Highlighting key scientific, technological, and regulatory milestones that have shaped the past decade of liquid biopsy innovation
• Identifying the most pressing challenges that still hinder broader adoption across trial phases, tumor types, and clinical settings
• Outlining the next strategic priorities needed to ensure liquid biopsies become a standard, validated tool for patient selection, monitoring, and treatment optimization in every clinical trial

• Reframing early detection as a strategic extension of drug development, not a departure from it
• Using ctDNA and emerging assays to guide earlier intervention, adjuvant decisions, and monitoring
• Aligning innovation with the ambition to eliminate cancer as a cause of death

• ctDNA as a predictive marker for therapeutic response and a potential surrogate for survival outcomes, enabling faster, more efficient trial designs
• ctDNA as an early, sensitive marker for tracking tumor burden and minimal residual disease (MRD), allowing for earlier intervention and better monitoring of disease progression
• Longitudinal ctDNA analysis for determining biologically active dosages, allowing for adjustments in dosage regimens to maximize efficacy while minimizing toxicity

A dedicated window for strategic one-to-one discussions and targeted networking, enabling attendees to strengthen key relationships and have purposeful conversations that drive meaningful outcomes in precision medicine.

• Gain a clear overview of the evolving liquid diagnostic partnership landscape, and how leading Dx players are positioning themselves across drug development programs
• Understand how strategic collaborations between biopharma and liquid biopsy partners are structured to align assay capability, regulatory strategy and commercial objectives
• Explore what differentiates high-value liquid Dx partners today, and how to select and manage partnerships that accelerate companion diagnostic readiness and clinical impact

• Turning ctDNA and MRD signals into faster, higher confidence go/no-go decisions across modalities
• Cutting years and cost from development by replacing slow endpoints with early molecular insight
• Making liquid biopsy work in the real world: global logistics, scalability, and ROI for sponsors

• Identifying the key knowledge gaps limiting ctDNA use in DLBCL, including variability in shedding, defining meaningful clearance thresholds, and linking molecular response to clinical decisions
• Confronting standardization challenges across assays and data pipelines to enable regulatory confidence and cross trial comparability
• Tackling logistical constraints and patient experience considerations to ensure ctDNA monitoring is feasible, timely, and truly beneficial in aggressive lymphoma settings

• Unpack the challenges with evidence generation in the MRD space
• Explain a solution that is emerging to catalyze MRD
• Evidence gaps

Join the liquid biopsy community for an interactive poster session, hosted by speakers, guests, and partners, showcasing pioneering ctDNA research, breakthrough LBx technologies and assays, and real-world solutions to accelerate clinical adoption.

The session is open for all registered stakeholders to attend, learn, ask questions and build new connections.

See full T&Cs on our website for eligibility.

• Outlining the evidence regulators expect for ctDNA endpoint consideration, including how multiple myeloma secured its first approval
• Identifying gaps between exploratory biomarker use and surrogate endpoint qualification
• Positioning ctDNA endpoints for inclusion in regulatory dialogue and submission packages

• Evaluating the clinical and analytical validation required for MRD to serve as a reliable surrogate endpoint across tumor types
• Aligning trial design, assay sensitivity, and timepoint selection to generate robust, regulator-ready evidence
• Exploring how MRD-driven endpoints could accelerate development timelines and inform earlier treatment decisions